UnityPoint Health - Des Moines

Lung Cancer Research Studies

Non-Small Cell

AFT-09: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy naive stage IV Non-small Cell Lung Cancer

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (screening trial for A081105, E4512 and EA5142)


Randomized Study of Erlotinib vs Observation Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (must be enrolled on screening trial A151216


A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (must be enrolled on screening trial A151216)


Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (must be enrolled on screening trial A151216)

BR001:  A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

LU002: Comparing Standard Treatment Alone to Radiation Therapy with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer

S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

S1507: Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following One or Two Prior Systemic Therapies

Small Cell

AFT-17: A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer

CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer